Oppenheimer reiterates Medtronic’s ‘Buy’ rating: 6 key notes

Oppenheimer gave Medtronic stock a “Buy” rating in a research note, according to Market Report.

Advertisement

Here are six facts:

 

1. Analysts gave the stock an $86.00 price target, revealing a 16.20 upside to the last closing price.

 

2. Wall Street sell-side analysts granted Medtronic a target price of $86.75.

 

3. Medtronic is projected to report earnings per share of $1.02 for the current fiscal quarter.

 

4. Medtronic last reported earnings of $1.16 for the period ending on April 30.

 

5. Sell-side analysts have a consensus mean earnings per share estimate of $4.39 for the current year.

 

6. The high end estimate of this year is $4.58 with the low being $4.19.

 

More articles on devices:
Intelligent Implant Systems closes funding round for spine system: 5 observations
Grand jury indicts troubled Texas spine surgeon — 5 key notes
Safe Orthopaedics SteriSpine proven effective: 5 things to know

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • From new technology acquisitions to regulatory clearances to leadership changes, here are 20 developments and updates from the biggest players…

  • SurGenTec’s ION-C earned FDA 510(k) clearance for ION-C navigation instruments with the ION-C posterior cervical facet fixation implant, according to…

  • VB Spine has made big pushes into the spine medtech space so far in 2026, including global expansions. Six headlines…

Advertisement

Comments are closed.